FEMALE GENITOURINARY ONCOLOGY SPECIAL FEATURE: REVIEW ARTICLE

Differentiating uterine sarcoma from leiomyoma: BET1T2ER Check!

INTRODUCTION
Uterine leiomyosarcomas are rare compared to leiomyomas, but it can be very difficult to tell these two entities apart. Clinical manifestations of uterine sarcomas and leiomyomas are similar, with increased uterine size, abdominal pain and per vaginal bleeding. Imaging therefore is crucial to be able to differentiate between these diagnoses as benign leiomyomas are amendable to conservative or benign intervention such as uterine fibroid embolisation or limited surgical resections, whereas the malignant sarcomas have a poor prognosis and early complete surgical removal is the optimal treatment to reduce future morbidity and mortality. Benign leiomyomas may have varied appearances on MR imaging with a significant proportion undergoing cystic or haemorrhagic degeneration or being highly cellular in appearance. The differing imaging features therefore provide a challenging imaging diagnostic environment where the stakes are high.

Overcalling of atypical leiomyomas as malignant entities will mean extensive surgery with uterine loss which may otherwise have been treated with less extensive surgery or a non-surgical approach. Conversely, undercalling a potential sarcoma results in delayed diagnosis and inappropriate management with potentially devastating consequences due to the aggressive nature of these lesions to metastasize, and therefore loss of the opportunity for intervention at the time of uterine limited disease. The subject is a topic of extensive research into the distinguishing MR imaging features which are discussed herein.

Imaging of leiomyomas vs uterine sarcomas
Ultrasound and CT do not have the soft tissue discrimination to aid diagnosis between uterine leiomyomas and sarcomas. Features of metastatic spread allow for easy distinction between benign and malignant lesions but are not always present or imaged at the time of initial concern. Metastatic disease is readily diagnosable on ultrasound and CT depending upon the site such as ascites, liver, lung or bone lesions or peritoneal deposits.

MRI is the best imaging modality for assessment of distinguishing features of leiomyomas from uterine sarcomas due to its ability to assess signal intensity of tissue with typical fibroid appearances of a whorled homogeneous low T2 weighted (T2WI) signal intensity (SI) lesion having a very high negative predictive value for a benign fibroid. The European Society of Urogenital Radiology (ESUR)'s guidelines provide a good rationale for basic and optional MRI sequences (Table 1). These sequences allow for assessment of...
SI, shape, outline of the lesion and disruption of boundaries such as the serosal and endometrial interfaces which are all helpful in characterising a suspicious lesion for malignancy compared to a benign fibroid. We propose an aide-memoire in this article to aid the reading in assessing these features: BET1T2ER Check:

Key features to identify sarcomas – BET1T2ER Check!

Given the low incidence of uterine sarcoma, there are limited comparable large-scale studies which have evaluated MRI features in leiomyomas and uterine sarcomas, such as leio-

myosarcoma (LMS). However, many small cohort studies have repeatedly highlighted several key features which can aid uterine sarcoma detection. The acronym BET1T2ER check can be used as an aide-memoire. Summary (Table 2) demonstrates key imaging features of uterine sarcomas and atypical leiomyomas.

### Table 1. MRI sequences – ESUR guidelines

| Sequence                  | Plane                                      | Rationale                           |
|---------------------------|--------------------------------------------|--------------------------------------|
| T2 Pelvis                 | Axial, Sagittal, and Coronal (optional) and axial oblique to uterus | Anatomy and characterisation         |
| T1 Pelvis                 | Axial                                      | Lymph node assessment and identify fat or haemorrhage within lesion |
| T1 Fat saturated pelvis    | Axial                                      | Identify fat or haemorrhage within lesion |
| T2                        | Fast axial of upper abdomen                | Assessment of upper abdominal viscera and lymph nodes |
| DWI                       | Axial                                      | Characterise atypical leiomyomas/sarcomas |
| ADC                       | Axial                                      | Characterise atypical leiomyomas/sarcomas |
| Post-gadolinum T1 (optimally DCE) | Best plane for characterisation            | Characterise of leiomyomas/sarcomas |

ADC, apparent diffusion coefficient; DCE, dynamic contrast-enhanced; DWI, diffusion-weighted imaging.

### Table 2. Summary of typical MRI imaging features for leiomyomas and sarcoma: BET1T2ER Check!

|                      | Typical leiomyoma                      | Hyaline & cystic degeneration | Red degeneration | Lipo-leiomyoma | Cellular leiomyoma | Sarcoma            |
|----------------------|----------------------------------------|------------------------------|-----------------|----------------|-------------------|--------------------|
| Border               | Well defined                           | Well defined                 | Well defined    | Well defined   | Well defined      | Lobulated or irregular |
| Enhancement          | Heterogeneous                          | Heterogeneous with no enhancement in degeneration | Heterogeneous with no enhancement in degeneration | Heterogeneous | Homogeneous | Heterogeneous – with irregular outline/ invasion |
| T1WI SI              | Low                                    | Low                           | Haemorrhage high | Fat high with saturation on fat saturated T1WI | Low               | Low with high SI in areas of haemorrhage |
| T2WI SI              | Low                                    | High in cystic areas          | Variable depending on age of haemorrhage | Variable given the fat containing component | Intermediate | Intermediate and heterogenous |
| Endometrial thickening| None                                   | None                          | None            | None           | None              | Direct involvement/ irregular or thickened |
| Restricted diffusion  | No                                     | No                            | No              | No             | Yes               | Yes                |
Degenerating leiomyomas also show areas without enhancement corresponding to the areas of degeneration. It is therefore vital that the signal intensity within these areas is compared to the standard $T_1$ weighted imaging ($T_1$WI) and $T_2$ weighted imaging ($T_2$WI) to characterise areas of hyaline, cystic or red cell degeneration which have typical signal intensities. In addition, uterine sarcomas demonstrate different enhancement characteristics to leiomyomas with sarcomas demonstrating increased mean contrast enhancement and early enhancement ratios compared to leiomyomas. This is a helpful defining characteristic which can be analysed using dynamic enhancement curves with an enhancement curve Type III with increased mean contrast enhancement and early enhancement ratios in sarcomas compared to leiomyomas.

$T_1$: $T_1$ weighted imaging – presence of haemorrhage
Subacute haemorrhage produces methaemoglobin, which demonstrates high $T_1$WI SI (Figures 2b, e, 3 and 4). This represents haemorrhagic necrosis and is seen in 18–94% of uterine sarcomas compared to 1.3–18% of leiomyomas. Intralesional haemorrhage has a high sensitivity (95–100%) and specificity (82–95%) for LMS (Figure 3). In a systematic review of nine studies, intralesional haemorrhage carried a 7.38 times increased risk of LMS compared to a benign lesion. Identification of blood products within the lesion is therefore very helpful for characterisation of sarcoma and is very unusual within a fibroid. An additional factor that helps in characterisation is that when haemorrhage does occur in a fibroid, it is usually due to a...
typical hormonal insult such as pregnancy or oral contraceptive use and the patient typically presents with an expected history of pain and systemic upset such as fever and leucocytosis. This occurrence is called red cell or carneous degeneration. If imaging is required in pregnancy to confirm diagnosis and exclude differential causes of fever and pain such as appendicitis, then the diagnosis can be made on $T_1$WI and $T_2$WI alone without the addition on intravenous contrast medium.

Figure 3. Comparison of imaging in LMS (a) and red cell degeneration of benign fibroid (b): Axial $T_1$W fat saturated MRI of two intrauterine lesions. Lesion (a) has diffuse hyperintense $T_1$W fat saturated signal with and irregular intermediate $T_1$ signal border and soft tissue projecting into the lesion (open white arrow). Lesion (b) has an intermediate to high $T_1$W fat saturated signal intensity with a hyperintense smooth rim and clear distinction of the margin with no internal projections (closed white arrow) in a 40-year-old lady. Surgical histology of lesion (a) confirmed LMS. Lesion (b) had been imaged with MRI 12 months previously, when it had low $T_1$W signal. Between the two MRIs, the female had become pregnant and given birth and the follow-up MRI was for further management of her benign leiomyoma, which had undergone red degeneration during pregnancy. LMS, leiomyosarcoma.

The presence of haemorrhage within a uterine mass in the absence of the clinical scenario compatible with red cell degeneration of a fibroid is therefore highly suggestive of a sarcoma. However, acute or chronic haemorrhage may not always be identified. Susceptibility-weighted imaging (SWI) or susceptibility weight angiography (SWAN) can detect deoxyhaemoglobin and haemosiderin and detect areas of previous haemorrhage. In a recent, but small study, low signal on SWAN sequences were detected in...
100% of uterine sarcomas compared to only 4% of leiomyomas (sensitivity 100% specificity 96%). However, SWI may be too sensitive to haemorrhage as other studies have produced similar results in leiomyomas with red degeneration. Other benign conditions such as adenomyosis can produce multiple small foci of signal voids, which is a pitfall.

**T2:** T2 weighted imaging – low T2 signal intensity dark areas

Low T2 signal intensity dark areas can be caused by flow voids or intraleision haemosiderin. Lakhman et al demonstrated good sensitivity (79–84%) and specificity (86%) for this feature in the diagnosis of LMS (Figure 5). It is unclear if this is an unrecognised or unreported feature, as a recent systematic review identified only 4% reported incidence for LMS with low T2 signal areas. These features should not be confused with normal low T2 signal seen in benign leiomyomas and, correlation with T1WI and enhancement is helpful.

High T2 signal intensity has been reported by many groups, but there can be considerable overlap with degenerating leiomyomas. A high T2 signal or T2 heterogeneity was not found to be significant in Lakhman et al’s study. In summary, the signal intensity on T2WI in sarcomas is variable as it depends upon the areas of necrosis, soft tissue, flow voids and haemosiderin.

**E: Endometrial involvement**

Adenosarcomas and ESS have a high propensity for endometrial involvement, the aggressive nature of LMS, means that although it originates within the myometrium it can also involve the endometrium in up to 35–50% of cases, resulting in loss or irregularity of the endometrial stripe (Figure 6). The outline of the lesion with the endometrium is therefore vital to assess as is the serosal surface for the same reason in cases suspicious for LMS.

**R: Restricted diffusion**

High diffusion-weighted imaging (DWI) SI (b = 800–1000 s mm$^{-2}$), greater than that of endometrium, and low ADC values (cut-off value: 0.79–1.27 $\times 10^{-3}$ mm$^2$ s$^{-1}$) have been found in LMS (Figure 7). However, the routine use of ADC value on its own is limited due to overlap with cellular leiomyoma values. Figure 7. Different cut-off values have been suggested. These cut-off values range between 0.79 and 1.27 $\times 10^{-3}$ mm$^2$ s$^{-1}$.
Differentiating uterine sarcoma from leiomyoma: BET1T2ER check!

In terms of benign lesions, Wahab et al. found that in cases where the DWI SI of the lesion was less than that of myometrium or greater than myometrium but less than that of endometrium or lymph nodes, then the lesion was almost certainly benign and conversely a DWI SI greater than endometrium and an ADC value less than or equal to $0.905 \times 10^{-3}$ mm$^2$ s$^{-1}$ had a high prediction for malignancy.

An important pitfall to be aware of is the misinterpretation of restricted DWI in areas of blood products and therefore the misinterpretation of benign red cell degeneration. Correlation of restricted DWI areas on both $T_2$ and $T_1$WI is therefore mandatory in interpretation of DWI findings.

**Leiomyomas**

Leiomyomas, or fibroids, are the most common benign uterine tumour with 20–80% of pre-menopausal females affected, although not all will have symptoms. Leiomyomas are comprised of smooth muscle tissue and excess extracellular fibrous supporting tissue and are under the hormonal influence of oestrogen and progesterone. They can occur at variety of different sites throughout the myometrium, such as subserosal, intramural and submucosal locations. During reproductive years, especially during pregnancy, leiomyomas can increase in size and typically reduce during post-menopausal period. Risk factors for leiomyomas can be found in Table 3. There is conflicting evidence on the effect of oral contraceptive on the development and growth of leiomyomas.

There are many options for treatment of fibroids, but it is important when reporting the imaging to recognise that in addition to medical and interventional radiology options the standard surgical options also now conserve the uterus. Laparoscopic or hysteroscopic myomectomy (often requiring morcellation), uterine artery embolisation (UAE), and high intensity focus ultrasound mean that the uterus remains in situ. Thus, an unexpected pre-operative uterine sarcoma may be spread throughout the abdominal cavity with techniques such as power morcellation, resulting in increased risk of recurrence and reduced survival. Because of this, the United States Food and Drug Administration issued a warning in 2014 and European Society of Gynaecological Endoscopy published a position statement in 2016 regarding worsening outcomes in patients with unsuspected uterine sarcomas who underwent leiomyoma morcellation. Limited studies suggest that UAE does not appear to cause dissemination but is strongly advised against if there is any concern about LMS as it delays appropriate treatment for LMS.

**Typical leiomyoma imaging features**

On MRI, these include low $T_2$WI lesions with a slightly whorled appearance, well-defined borders with no invasion. Enhancement often follows that of myometrium. They can be located throughout the myometrium in a subserosal, intramural or submucosal distribution, with the FIGO PALM-COEIN classification.

**Atypical leiomyomas**

Atypical leiomyomas may have several histological features which can be easily recognised on MR imaging:

- Oedema

Peripheral or diffuse heterogenous high $T_2$WI on the background of low $T_2$WI signal intensity with normal enhancement may indicate oedema. This may be the first sign of degeneration.

- Degeneration

Degeneration tends to occur in leiomyomas >5 cm and can be:

(i) **Hyaline (60%)**

MRI characteristics may not change significantly, as the collagen deposited in hyaline degeneration is usually low.

| Risk factors for leiomyomas |
|----------------------------|
| Race               | African ancestors > other races |
| Genetic            | e.g. hereditary leiomyomatosis and renal cell carcinoma |
| Diet               | High consumption of red meat Reduced intake of vegetables, fruit and vitamin D |
| Gynaecology history| Multiparity, polycystic ovarian syndrome, hormone replacement therapy |

Figure 7. Comparison of DWI imaging in benign (a, b) and malignant (c, d) lesions: axial DWI (a) and ADC (b) of a highly cellular leiomyoma and axial DWI (c) and ADC (d) of a leiomyosarcoma. The DWI outline is helpful in demonstrating the irregular outline in the malignant lesion (c, d). ADC, apparent diffusion coefficient; DWI, diffusion-weighted imaging.

$10^{-3}$ mm$^2$ s$^{-1}$ and may be due to different MRI machines, field strengths and study design.
signal intensity on $T_2$ and intermediate on $T_1$WI. Very little or no contrast enhancement will be seen within hyaline areas due to the accumulation of proteinaceous material in the extracellular space preventing gadolinium entering.

(ii) Cystic (4%)
This is characterised by high $T_2$ and low $T_1$WI spaces with a thin low $T_2$ signal rim and associated enhancement, representing residual leiomyoma tissue.

(iii) Myxoid (uncommon)
This is due to myxoid matrix and extracellular mucin deposition and demonstrates high $T_2$ and low $T_1$ signal intensity but with contrast medium enhancement.

(iv) Red/haemorrhagic or carneous (Figure 3)
This occur in leiomyomas during pregnancy or with oral contraceptive use. Torted fibroids may also become ischaemic and haemorrhagic. Peripheral or diffuse high $T_1$ signal intensity is seen, with corresponding low $T_2$ signal due to blood degradation products. There is no contrast enhancement.

Other atypical leiomyomas may present with a different spectrum of signal intensities. These include:

- **Cellular leiomyoma** (Figure 7a) (Rare)
  They are typically well-defined and mildly hyperintense on $T_2$WI due to high cellularity. With homogenous contrast enhancement. Due to their high cellularity, these leiomyomas often demonstrate restricted diffusion.

- **Lipoleiomyoma** (Figure 9)
  These are rare leiomyoma containing mature macroscopic fat. High $T_1$ signal intensity within the leiomyoma, which suppresses on fat suppressed sequences is characteristic. Fat attenuation can be seen on CT. Some lipoleiomyomas contain microscopic fat which can only be detected on in-and-out of phase sequences. The appearance of fat is regarded as characteristic for lipoleiomyoma as liposarcoma arising within the uterus is extremely rare.

- **Intravascular leiomyomas** (Figure 10)
  This rare condition is characterised by aggressive intravenous growth of a leiomyoma. The involved veins may be intra- or extraterine and include major veins of the pelvis and abdomen (Figure 10). In 10–40%, the heart can be involved. MRI characteristics depend on the amount of smooth muscle and fibrous components in the tumour, but characteristically have similar appearances to benign or cellular leiomyomas. Surgical resection and hormone treatment is required.

- **Benign metastasising leiomyomas**
  This rare and unusual condition occurs when benign leiomyomas metastasise to other organs distant from the uterus. Lung metatases are most common and are often found incidentally on chest X-ray or imaging for other conditions. The tumours are under hormonal influence and can spontaneously resolve. They can sometimes cavitate and may cause a pneumothorax but rarely
calcify. The metastases are otherwise non-specific on CT or MRI and can mimic malignant metastases, sarcoidosis, amyloidosis and rheumatoid nodules. Patients often have a past medical history for treated leiomyomas, such as hysterectomy.

- Parasitic, peritoneal and retroperitoneal leiomyomatosis

All these entities are rare but together describe the presence of leiomyomas separate to the uterus in different abdominal and pelvic locations. In parasitic leiomyomas, the leiomyomas originate from the uterus and subsequently develop a blood supply from their surroundings before loosening their attachment with the uterus. Common sites include broad ligament, ovary, bladder, ureter and urethra. They have similar imaging characteristics to benign leiomyoma but can mimic lymphadenopathy or benign or malignant tumours. Broad ligament tumours can be associated with a raised CA125 and pseudo-Meig’s syndrome. These leiomyomas can also undergo degenerative changes and developing imaging characteristics similar to atypical leiomyoma within the uterus.

In peritoneal leiomyomatosis, multiple leiomyoma grow within the abdominal cavity on the peritoneum and omentum typically from seeding from previous surgery. It is often identified incidentally and is associated with increased levels of progesterone and oestrogen such as pregnancy, oral contraceptive use and oestrogen-producing tumours such as granulosa cell tumours. Rounded nodules can be seen throughout the peritoneal cavity which have the same signal characteristics as muscle on MRI. Abdominal appearances can mimic peritoneal or ovarian carcinoma, mesothelioma, dermoid tumours and tuberculosis.

Retroperitoneal leiomyomatosis is often found incidentally and given the location in the retroperitoneum can mimic other retroperitoneal pathology including lymphoma.

- Smooth muscle tumours of uncertain malignant potential (STUMP) (Figure 12)

These are rare tumours with some concerning features on pathology (in addition to imaging), such as nuclear atypia, necrosis and mitotic figures, but cannot be formally classified as malignant. They therefore represent a separate category according to pathological diagnosis and not surprisingly, they have a variety of MRI appearances from typical benign leiomyoma appearances to a classical leiomyosarcoma appearances.

Uterine sarcomas

Uterine sarcomas are uncommon making up 1% of all gynaecological tract and 8% of all uterine malignancies. Of uterine sarcomas, the most common are endometrial stromal sarcoma (ESS) and leiomyosarcoma (LMS). Other rare sarcomas include uterine lymphoma, malignant fibrous histiocytoma and rhabdomyosarcoma. It is important to be able to differentiate uterine sarcoma from leiomyoma as the treatment and prognosis are different.
sarcomas, LMS is the most common type comprising 70% of cases. LMS are found incidentally in 0.09–0.49% of hysterectomy specimens.45–47 However, it is important to remember that benign smooth muscle tumours of the uterus are extremely common and only about 1/1000 uterine smooth muscle tumours are sarcomas.

Risk factors for leiomyosarcomas and other uterine sarcomas are not well understood (Table 4). Older age at menarche (i.e. menarche at >15 years vs <11 years) and tubal ligation are protective.49

(a) Leiomyosarcoma (Figure 1)
- The majority of LMS arise de-novo within the myometrium with only 0.2% arising within a pre-existing leiomyoma.48,50,51

(b) Endometrial stromal sarcomas (Figure 2a–c)
- These account for 10–15% of uterine sarcomas and can be divided into low (LGESS) and high grade (HGESS).51 Younger females (average 39 years) tend to be diagnosed with LGESS while post-menopausal females (average 61 years) more commonly have HGESS. LGESS has a good prognosis and can have a worm like or nodular appearance on MRI as the tumour extends through the myometrium and serosa54 (Figure 2a–c).

(c) Undifferentiated sarcomas
- These sarcomas have a poor prognosis, especially if vascular invasion or haematological spread are present. They are often endometrial in location and can be detected on pre-operative endometrial biopsy.

(d) Adenosarcomas (Figure 2d–f)
- These are rare slow-growing uterine sarcomas which account for 5.5–9% of all uterine sarcomas.55 They are composed of malignant sarcomatous elements and benign glandular tissue and tend to occur within the endometrial cavity in 70% of cases. Myometrial, cervical and ovarian locations have also been described, and are more commonly seen in younger patients.55,56 Sarcomatous overgrowth (>25%) can occur which results in poorer prognosis. Myometrial and lymphovascular invasion are further poor prognostic signs, with 33% recurring within 5 years of diagnosis.

(e) Carcinosarcoma
- Carcinosarcomas have recently been reclassified as an aggressive form of endometrial carcinoma57 rather than true uterine sarcoma. They have both sarcomatous and carcinoma elements, which include endometrioid, serous, squamous, adenocarcinoma or a mix of different types.

Molecular studies have demonstrated differences in microRNA expression and biomarkers between leiomyomas and LMS suggesting separate aetiologies and developmental pathways.52,53 Although LMS can invade into the endometrium, pre-operative endometrial biopsy has been shown to only detect approximately 35–50% of cases.16,17

Table 4. Risk factors for uterine sarcoma48

| Risk factors for Uterine sarcomas | Age >40 years |
|----------------------------------|--------------|
| Obesity                          | >30 kg m⁻² vs <25 kg m⁻² |
| Other medical conditions         | Diabetes, previous radiotherapy, long term tamoxifen use |

Typical uterine sarcoma MR imaging features
A typical LMS will present as a large tumour with irregular borders, areas of intralesional haemorrhage, necrosis and early central enhancement in the soft tissue part of the tumour at 40–60s post-i.v. contrast medium administration.6 In some cases, extraterine spread is seen, including ascites and peritoneal
Differentiating uterine sarcoma from leiomyoma: BET1T2ER check!

EBT1T2ER

Differentiating uterine sarcoma from leiomyoma: BET1T2ER check!

18,21,58 (Figure 1). Other types of uterine sarcoma have slightly different appearances.

ESS tend to form heterogenous high T2 and low T1 signal intensity polypoid masses within the endometrial cavity, with 'bag of worms' appearance from serpiginous high T2 SI tumour spreading along and compressing smooth muscle fibres.21,58,59 Necrosis, and haemorrhage are also features in ESS as in LMS (Figure 2a–c). Contrast enhancement of these tumours is often heterogeneous, iso- or hypertense compared to the myometrium, whilst endometrial cancer often demonstrates hypoenhancement compared to the myometrium.48,59

Adenosarcomas are also large polypoid masses within the endometrial cavity (Figure 2d–f), causing it to expand and tumour can prolapse through the cervical canal. These tumours can have both glandular cystic spaces or necrosis, producing high T2 signal intense foci and can mimic trophoblastic disease. The polypoid 'ladelike' appearance in addition to the solid components can also be confused with a benign polyp but the heterogeneity is helpful in distinguishing. Solid components will enhance with contrast medium. Myometrial invasion, haemorrhage and necrosis can occur with sarcomatous overgrowth. On DWI high b values, adenosarcomas can show low signal intensity, which is an indication of their low grade.51,60,61 Unenhanced regions can also be seen in carcinosarcomas, and although this in itself is not a poor prognostic sign, when necrosis comprises ≥10% of the total tumour, it is correlated with poor prognosis.62

Combining features and algorithms

Although some of the features described in BET1T2ER check give a high sensitivity and specificity for uterine sarcomas, especially LMS, there is still overlap with atypical leiomyomas. Combining features improves the sensitivity, specificity and accuracy for the diagnosis of uterine sarcoma.

Most studies are small and have identified different imaging or clinical features to differentiate uterine sarcomas from leiomyomas.

Lakhman et al5, whose study with 19 confirmed LMS and 22 atypical leiomyomas, demonstrated increased specificity and sensitivity for LMS of 95–100% when 3 or more of the following MRI features were identified; irregular borders, T1 hyperintense signal, T2 dark areas and central unenhanced areas.

Similarly, Thomassin-Naggara et al’s study of 25 uncertain or malignant sarcomas and 26 leiomyomas identified that high DWI b1000 signal intensity, mean ADC value of <1.23×10−3 mm2 s−1 and an intermediate T1W signal intensity distinguished 92.4% of uterine sarcoma from benign leiomyomas.

These features are similar to those identified in a large recent case controlled retrospective study. The development of an algorithm for the presence of lymphadenopathy, DWI signal greater than that of endometrium and low ADC ≤ 0.095 × 10−3 mm2 s−1 provided high sensitivities and specificities for experienced (88 and 100%) and less experienced readers (83 and 97%). The group also demonstrated that the combined features of low T2 signal solid regions (i.e. enhancing benign typical fibroid tissue compared to T2 dark area low signal voids or haemosiderin in uterine sarcoma), low DWI signal of the myometrial lesion compared to endometrium and no lymph nodes or ascites allowed correct diagnosis of a benign uterine lesion in 100% of their cases.18

A simple decision tree developed by machine learning techniques on 84 benign and 21 malignant lesions also demonstrated that predominantly high T1W signal, restricted diffusion and central necrosis as important features with a 100% sensitivity and 95% specificity.15 This simple decision tree demonstrated that lesions which did not have these features were likely to be benign. Only four benign lesions were misclassified as malignant using the simple algorithm, while none of the malignant lesions were misclassified.

Goto et al6 suggest combining clinical and biochemical markers with MRI features. They demonstrated improved diagnosis when using contrast enhanced MRI over unenhanced MRI in a study of 10 LMS and 130 leiomyomas with degeneration. They showed that tumour contrast enhancement at 60 s after administration of Gd-DTPA was detected in all LMS, but absent in 28 of 32 of their leiomyoma patients. This feature improved the positive predictive value from 52.6 to 83.3% and their diagnostic accuracy from 93.1 to 95.2%. When they combined contrast enhanced MRI features with serum lactate dehydrogenase measurements, the specificity, PPV and diagnostic accuracy increased to 100%,5 Patient age ≥44 years old also demonstrated increased sensitivity (82.4%) and specificity (92.2%) of LMS over leiomyomas.65 This has led to some centres combining imaging, biochemical and other features such as endometrial biopsy formally or converting open myomectomy procedures when a case is indeterminate pre-operatively. This was evaluated in the study by Nagai et al64 who used combined imaging, biochemical and pathological pre-operative features in a formal Preoperative Sarcoma Score (PRESS) with an accuracy rate of prediction of sarcoma of 84.1% using this score.

Although many of the MRI features and the use of contrast enhancement has been included in latest European imaging guidelines, the combination with LDH measurements has not been included,3 which may be because LDH can also be raised in cellular and degenerating leiomyomas.6

Other techniques and modalities

Lakhman et al3 used advanced processing texture analysis techniques of regions of interest on the T1W images. Using these techniques, they demonstrate increased textural heterogeneity but reduced entropy in LMS compared to atypical leiomyomas. In a further texture analysis study of LMS and leiomyomas, multiple MRI sequences were assessed. Gerges et al63 demonstrated T2 and T1 solid area texture analysis were most useful while ADC maps analysis was not significantly different between the two lesions. Although this is still a research technique, it suggests that potential computer analysis of current standardised MRI sequences could be used to improve diagnostic accuracy in the future.
Several groups have investigated the use of PET/CT in distinguishing uterine sarcomas from leiomyomas. In a recent small 18F-FDG-PET/CT study of 34 uterine sarcomas, the SUVmax cut-off <4.4 had a 100% negative predictive value for a uterine sarcoma, and therefore absence of uptake is very helpful in excluding LMS with a high SUVmax being associated with a worse prognosis. However, the specificity of PET/CT is reduced compared to MRI.

3'-deoxy-3'-18F-fluorothymidine PET (18F-FLT-PET) allows assessment of tumour proliferation without uptake of the tracer agent by inflammatory tissues. It has been shown to be superior to 18F-FDG-PET/CT in distinguishing uterine sarcomas from leiomyomas and tracer uptake correlates with immunohistochemical indices of cellular proliferation. However, it is not commonly available in routine clinical practice.

SUMMARY

Although uterine sarcomas are rare, it is vital to raise suspicion on pre-operative imaging to provide timely priority referral for appropriate surgical planning. MRI is the best modality for assessing uterine sarcomas with CT used for assessment of distant spread. Atypical leiomyomas which have undergone degeneration, are cellular, metastasising or intravascular leiomyomas all have at least one key feature that can mimic diagnostic of LMS on MRI but combining MR imaging features and taking into account the clinical scenario are helpful. Identifying these key MR imaging features such as irregular Borders, heterogenous Enhancement with central poor enhancement, hyperintense T1W signal in keeping with haemorrhage, T2 dark areas from vascular signal voids and haemosiderin, Endometrial invasion and restricted diffusion together aids successful pre-operative suspicion for sarcoma with the combination increasing sensitivity, specificity and accuracy. These can be remembered as the acronym BET1 T2 ER check.

REFERENCES

1. Wu T-I, Yen T-C, Lai C-H. Clinical presentation and diagnosis of uterine sarcoma, including imaging. Best Pract Res Clin Obstet Gynaecol 2011; 25: 681–9. doi: https://doi.org/10.1016/j.ypobgyn.2011.07.002
2. Thomassin-Naggara I, Dechoux S, Bonneau C, Morel A, Rouzier R, Carette M-F, et al. How to differentiate benign from malignant myometrial tumours using MR imaging. Eur Radiol 2013; 23: 2306–14. doi: https://doi.org/10.1007/s00330-013-2819-9
3. Kubit-Huch RA, Weston M, Nougaret S, Leonhardt H, Thomassin-Naggara I, Horta M, et al. European Society of urogenital radiology (ESUR) guidelines: MR imaging of leiomyomas. Eur Radiol 2018; 28: 3125–37. doi: https://doi.org/10.1007/s00330-017-5157-5
4. Bi Q, Xiao Z, Lv F, Liu Y, Zou C, Shen Y. Utility of clinical parameters and multiparametric MRI as predictive factors for differentiating uterine sarcoma from atypical leiomyoma. Acad Radiol 2018; 25: 993–1002. doi: https://doi.org/10.1016/j.acra.2018.01.002
5. Lakhman Y, Veeraraghavan H, Chaim J, Feier D, Goldman DA, Moskowitz CS, et al. Differentiation of uterine leiomyosarcoma from atypical leiomyoma: diagnostic accuracy of qualitative MR imaging features and feasibility of texture analysis. Eur Radiol 2017; 27: 2903–15. doi: https://doi.org/10.1007/s00330-016-4623-9
6. Goto A, Takeuchi S, Sugimura K, Maruo T. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma of the uterus. Int J Gynecol Cancer 2002; 12: 354–61. doi: https://doi.org/10.1046/j.1525-1438.2002.01086.x
7. Lin G, Yang L-Y, Huang Y-T, Ng K-K, Ng S-H, Ueng S-H, et al. Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma / smooth muscle tumor with uncertain malignant potential and benign leiomyoma. J Magn Reson Imaging 2016; 43: 333–42. doi: https://doi.org/10.1002/jmri.24998
8. Tanaka YO, Nishida M, Tsunoda H, Okamoto Y, Yoshikawa H. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings. J Magn Reson Imaging 2004; 20: 998–1007. doi: https://doi.org/10.1002/jmri.20207
9. Bolan C, Caserta MP. Mr imaging of atypical fibroids. Abdom Radiol 2016; 41: 2332–49. doi: https://doi.org/10.1007/s00261-016-0935-0
10. Takeuchi M, Matsuzaki K, Harada M. Carcinosarcoma of the uterus: MR findings including diffusion-weighted imaging and MR spectroscopy. Acta Radiol 2016; 57: 1277–84. doi: https://doi.org/10.1177/0284185115626475
11. Takeuchi M, Matsuzaki K, Harada M. Clinical utility of susceptibility-weighted MR sequence for the evaluation of uterine sarcomas. Clin Imaging 2019; 53: 143–50. doi: https://doi.org/10.1016/j.clinimag.2018.10.015
12. Ando T, Kato H, Furui T, Morishige K-I, Goshima S, Matsuou M. Uterine smooth muscle tumours with hyperintense area on T1 weighted images: differentiation between leiomyosarcomas and leiomyomas. Br J Radiol 2018; 91: 20170767. doi: https://doi.org/10.1259/bjr.20170767
13. Kaganov H, Adas E, Fraser DS. Preoperative magnetic resonance imaging diagnostic features of uterine leiomyosarcomas: a systematic review. Int J Technol Assess Health Care 2018; 34: 172–9. doi: https://doi.org/10.1017/S0266462318000168
14. Takeuchi M, Matsuzaki K, Bando Y, Harada M. Evaluation of red degeneration of uterine leiomyoma with susceptibility-weighted MR imaging. Magn Reson Med Sci 2019; 18: 158–62. doi: https://doi.org/10.2463/mrms.mp.2018-0074
15. Malek M, Tabbian E, Rahimi Dehghan M, Rahmani M, Akhavan S, Sheikh Hasani S, et al. A diagnostic algorithm using multi-parametric MRI to differentiate benign from malignant myometrial tumors: Machine-Learning method. Sci Rep 2020; 10: 7404. doi: https://doi.org/10.1038/s41598-020-64285-w
16. Skorstad M, Kent A, Lieng M. Preoperative evaluation in women with uterine leiomyosarcoma. A nationwide cohort study. Acta Obstet Gynecol Scand 2016; 95: 1228–34. doi: https://doi.org/10.1111/aogs.13008
17. Peters A, Sadecky AM, Winger DG, Guido RS, Lee TTM, Mansuria SM, et al.
Characterization and preoperative risk analysis of leiomyosarcomas at a high-volume tertiary care center. Int J Gynecol Cancer 2017; 27: 1183–90. doi: https://doi.org/10.1097/IGC.0000000000001094

18. Abdel Wahab C, Jannot A-S, Bonaffini PA, Bourillon C, Cornou C, Lefrere-Belda M-A, et al. Diagnostic algorithm to differentiate benign atypical leiomyomas from malignant uterine sarcomas with diffusion-weighted MRI. Radiology 2020; 297: 361–71. doi: https://doi.org/10.1148/radiol.2020191658

19. Tamai K, Koyama T, Saga T, Morisawa N, Fujimoto K, Mikami Y, et al. The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol 2008; 18: 723–30. doi: https://doi.org/10.1007/s00330-007-0787-7

20. Sato K, Yuasa N, Fujita M, Fukushima Y. Differentiating uterine sarcoma from leiomyoma: BET1T2ER check!BJR

22. Namimoto T, Yamashita Y, Awai K, Nakaura T, Y anaga Y, Hirai T, et al. Combined use of T2- and diffusion-weighted 3-T MR imaging for differentiating uterine sarcomas from benign leiomyomas. J H, Oram DH, Reznek RH. Mr imaging of uterine sarcomas. Radiology 2012; 267: e50058. doi: https://doi.org/10.1002/cncr.28844

24. Sun S, Bonaffini PA, Nougaret S, Darai E, Rouzier R. Value of imaging for preoperative differentiation of uterine leiomyomas treated with uterine artery embolization. Best Pract Res Clin Obstet Gynaecol 2015; 29: 305–27. doi: https://doi.org/10.1016/j.bpobgyn.2015.11.012

25. Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F. Epidemiology and risk factors of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2018; 46: 3–11. doi: https://doi.org/10.1016/j.bpbgyon.2017.09.004

27. Park J-Y, Park S-K, Kim D-Y, Kim J-H, Kim Y-M, Kim Y-T, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol 2011; 122: 255–9. doi: https://doi.org/10.1016/j.ygyno.2011.04.021

28. Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. Plast Reconstr Surg 2012; 7: e50058. doi: https://doi.org/10.1097/PLR.0b013e31822f58c8

29. George S, Barysaukas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, et al. Retrospective cohort study evaluating the impact of intraoperative morcellation on outcomes of localized uterine leiomyosarcoma. Cancer 2014; 120: 3154–8. doi: https://doi.org/10.1002/cncr.28844

30. US Food and Drug Administration. UPDATED—laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. Silver Spring: US Food and Drug Administration; 2014. https://wayback.archive-it.org/7993/20170722157277/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm.

31. European Society for Gynaecological Endoscopy,SGE statement on morcellation. 2016. Available from: https://esge.org/wp-content/uploads/2017/02/ESGE-Statement-on-Morcellation-02-May-2014.pdf.

32. Kainsbak J, Hansen ES, Dohoum M, Literature review of outcomes and prevalence and case report of leiomyosarcomas and non-typical uterine smooth muscle leiomyoma tumors treated with uterine artery embolization. Eur J Obstet Gynecol Reprod Biol 2015; 191: 130–7. doi: https://doi.org/10.1016/j.ejogrb.2015.05.018

33. Whitaker L, Critchley HOD. Abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol 2016; 34: 54–65. doi: https://doi.org/10.1016/j.bpobgyn.2015.11.012

34. Ueda H, Togashi K, Konishi I, Kataoka ML, Koyama T, Fujwara T, et al. Unusual appearances of uterine leiomyomas: MR imaging findings and their histopathologic backgrounds. Radiographics 1999; 19 Spec No. S31–45. doi: https://doi.org/10.1148/ radiographics.19suppl_1.s39004s131

35. Peng H-J, Zhao B, Yao Q-W, Qi H-T, Xu Z-D, Liu C. Intravenous leiomyomatosis: CT findings. Abdom Imaging 2012; 37: 628–31. doi: https://doi.org/10.1007/s00261-011-9798-6

36. Kocica MJ, Vranes MR, Kostic D, Kovacevic-Kostic N, Lackovic V, Bozic-Mihajlovic V, et al. Intravenous leiomyomatosis with extension to the heart: rare or underestimated? J Thorac Cardiovasc Surg 2005; 130: 1724–6. doi: https://doi.org/10.1016/j.jtcvs.2005.08.021

37. Andrade LA, Torresan RZ, Sales IF, Vicentini R, De Souza GA. Intravenous leiomyomatosis of the uterus. A report of three cases. Pathol Oncol Res 1998; 4: 44–7. doi: https://doi.org/10.1007/BF02904695

38. Evans AT, Symmonds RE, Gaffey TA. Recurrent pelvic intravenous leiomyomatosis. Obstet Gynecol 1981; 57: 260–4.

39. Shin MS, Fulmer JD, Ho KJ. Unusual computed tomographic manifestations of benign metastasizing leiomyomas as caviary nodular lesions or interstitial lung disease. Clin Imaging 2019; 45–9. doi: https://doi.org/10.1016/j.clinimag.2019.07.007

40. Kain PK, Prasad Shantshogue AK, Macdonald DB, Fraser-Hill MA, Papadatos D, Kielar AZ, et al. Leiomyomas beyond the uterus: unusual locations, rare manifestations. Radiographics 2008; 28: 1931–48. doi: https://doi.org/10.1148/rg.287085095

41. Abramson S, Gilkeson RC, Goldstein JD, Woodward PK, Eisenberg R, Abramson N. Benign metastasizing leiomyoma: clinical, imaging, and pathologic correlation. AJR Am J Roentgenol 2001; 177: 1409–13. doi: https://doi.org/10.2214/ajr.176.6.1761409

42. Brown RS, Marley JL, Cassoni AM. Pseudo-Meigs’ syndrome due to broad ligament leiomyoma: a mimic of metastatic ovarian carcinoma. Clin Oncol 1996; 10: 198–201. doi: https://doi.org/10.1097/01.S0936-6555(98)80071-X.

43. Sala EJS, Attri M. Magnetic resonance imaging of benign adnexal disease. Top Magn Reson Imaging 2003; 14: 305–27. doi: https://doi.org/10.1097/01.mri.2003080000-00004

44. DeMulder D, Ascher SM. Uterine leiomyosarcoma: can MRI differentiate leiomyosarcoma from benign leiomyoma before treatment? AJR Am J Roentgenol 2018; 211: 1405–15. doi: https://doi.org/10.2214/AJR.17.19234

45. Zhao W-C, Bi F-F, Li D, Yang Q. Incidence and clinical characteristics of unexpected uterine sarcoma after hysterectomy and myomectomy for uterine fibroids: a retrospective study of 10,248 cases. Onco Targets Ther 2015; 8: 2943–8. doi: https://doi.org/10.2147/OTT.S92978

46. Wright JD, Tergas AI, Cui R, Burke WM, Hou JY, Ananth CV, et al. Use of electric power morcellation and prevalence of underlying cancer in women who undergo myomectomy. JAMA Oncol 2015; 1: 69–77. doi: https://doi.org/10.1001/jamaoncol.2014.206
53. Danielson LS, Menendez S, Attolini CS-O, Guijarro MV, Bisognia M, Wei J, et al. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. *Am J Pathol* 2010; 177: 908–17. doi: https://doi.org/10.2353/ajpath.2010.091150

54. Conklin CMJ, Longacre TA. Endometrial stromal tumors: the new who classification. *Adv Anat Pathol* 2014; 21: 383–93. doi: https://doi.org/10.1097/PAP.0000000000000446

55. Tse KY, Crawford R, Ngan HY. Staging of uterine sarcomas. *Best Pract Res Clin Obstet Gynaecol* 2011; 25: 733–49. doi: https://doi.org/10.1016/j.bpo.2011.05.011

56. D’Angelo E, Prat J. Uterine sarcomas: a review. *Gynecol Oncol* 2010; 116: 131–9. doi: https://doi.org/10.1016/j.ygyno.2009.09.023

57. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynaecol Obstet* 2009; 105: 103–4. doi: https://doi.org/10.1016/j.ijgo.2009.02.012

58. Koyama T, Togashi K, Konishi I, Kobayashi R, Abiko K, Hamanishi J, et al. Unenhanced MR imaging of uterine leiomyoma. *Ann Nucl Med* 2012; 16: 28–33. doi: https://doi.org/10.1007/s12149-012-0409-0

59. Ueda M, Otsuka M, Hatakenaka M, Sakai M, Ueda H, Kataoka ML, et al. Mr imaging of endometrial stromal sarcoma: correlation with pathologic findings. *Am J Roentgenol* 1999; 173: 767–72. doi: https://doi.org/10.2214/ajr.173.3.10470920

60. Y oshizako T, Wada A, Kitagaki H, Ishikawa H, Ueda H, Kataoka ML, et al. Mr imaging findings of uterine endometrial stromal sarcoma: differentiation from endometrial carcinoma. *Eur Radiol* 2001; 11: 28–33. doi: https://doi.org/10.1007/s003300000541

61. Nakamura A, Ueda M, Ono M, Yoshimatsu K, et al. Mr imaging of uterine leiomyosarcoma: case report and literature review. *Magn Reson Med Sci* 2011; 10: 251–4. doi: https://doi.org/10.2463/mrms.10.251

62. Takeuchi M, Matsuzaki K, Nishitani H, Hanaoka T, Uotani T, et al. Novel uterine sarcoma preoperative diagnosis score predicts the need for surgery in patients presenting with a uterine mass. *Springerplus* 2014; 3: 678. doi: https://doi.org/10.1186/s40064-014-0678-5

63. Gorges L, Popiolek D, Rosenkrantz AB. Explorative investigation of Whole-lesion histogram MRI metrics for differentiating uterine leiomyomas and leiomyosarcomas. *AJR Am J Roentgenol* 2018; 210: 1172–7. doi: https://doi.org/10.2214/AJR.17.18605